1,043 reports of this reaction
2.8% of all VALPROATE SODIUM reports
#4 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #4 most commonly reported adverse reaction for VALPROATE SODIUM, manufactured by Fresenius Kabi USA, LLC. There are 1,043 FDA adverse event reports linking VALPROATE SODIUM to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 2.8% of all 37,274 adverse event reports for this drug.
Patients taking VALPROATE SODIUM who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is a less commonly reported adverse event for VALPROATE SODIUM, but still significant enough to appear in the safety profile.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for VALPROATE SODIUM:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 1,043 FDA reports for VALPROATE SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 2.8% of all adverse event reports for VALPROATE SODIUM, making it a notable side effect.
If you experience foetal exposure during pregnancy while taking VALPROATE SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.